RIDDLE&CODE
5.4.2022 10:17:07 CEST | Business Wire | Press release
RIDDLE&CODE Energy Solutions, a 50:50 joint venture between Wien Energie and RIDDLE&CODE, has joined the 2Tokens consortium as a founding member for the Energy Token working group. After having been an associated partner since 2020, the company’s decision to become an active contributor is a consequent step on its path to developing an international service portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405005131/en/
The main goal of the collaboration is to turn 2Tokens into the leading European consortium in the industrial blockchain and finance space, representing and supporting the most relevant projects. "We have proven the technical and economic viability of tokenizing energy assets in several individual projects at the regional level. Now it is time to think on a larger scale. The token standards being developed at 2Tokens will most likely have a decisive impact on the future standards of the European energy market,” says Kai Siefert, the newly appointed managing director of RIDDLE&CODE Energy Solutions.
“The joining of a true pioneer such as RIDDLE&CODE Energy Solutions will significantly strengthen European collaboration in the tokenization sector,” underlines Alex Bausch, Executive Chairman of 2Tokens. “RIDDLE&CODE Energy Solutions plays an important role in the adoption of tokenization technology in commercial projects with interoperable banking grade solutions. Our working groups on the EURO stable coin and Energy Tokens are paramount to the joint mission for mass adoption of token technology in the energy industry. “
Next steps: Apart from driving things forward in the 2Tokens working groups, leading 2Tokens members, as well as the RIDDLE&CODE group companies, will discuss commercial partnerships in the areas of Custody of Digital Assets, Tokenization platforms and blockchain hardware research. "For critical infrastructures and in order to turn our European values of democratic governance and the Rule of Law into efficient backend solutions, we need infrastructure that is secure from end-to-end. Crypto hardware anchors will play a key role in this, and that's why 2Tokens is excited to have RIDDLE&CODE joining as the leading European blockchain interface company,” says Jos Röling, Captain of the Energy working group.
About RIDDLE&CODE Energy Solutions
RIDDLE&CODE Energy Solutions provides the blockchain-powered infrastructure that enables resilient, decentralized and fully decarbonized energy markets. With the development of the MyPower platform, the company has shown an effective way for energy players to move into the machine economy. By tokenizing energy, machines, and data, RIDDLE&CODE Energy Solutions significantly increases the liquidity of distributed assets, making them easily accessible to broad investor segments, while their output can be traded and tracked with unprecedented transparency and security.
More information about MyPower: www.riddleandcode.com/energy
About 2Tokens
2Tokens has the ambition to raise awareness, stimulate relevant discussions, and bring together knowledge/expertise to reduce the barriers to the adoption of tokenization and help realise wider social benefits. The mission of 2Tokens is to formulate a guide, as part of a larger vision, for any type of organisation that wants to leverage token technology. It aims to come to a shared understanding of token finance and, as such, is a public-interest initiative supported by a diverse community of technology companies, policymakers, financial advisors, banks, and legal & regulatory experts and academia. 2Tokens is a non-profit organisation funded in part by the European Union and Industry partners with the endorsement of the Erasmus University Rotterdam, government and several industry players.
More information: www.2tokens.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005131/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom